For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Onyx Pharmaceuticals, Inc.

USPTO Granted Patents = 58

EPO Patents = 1

Trademarks = 1

Forward Citations = 850

Loading Chart...

Loading Chart...

68 inventors (with patents filed for the assignee):

Terry Hermiston (9 out of 30 patents)

Arie Abo (8 out of 13 patents)

Len Stephens (8 out of 8 patents)

4. Sylvie Laquerre (7 out of 10 patents)

5. Yuqiao Shen (6 out of 6 patents)

6. Ali Fattaey (6 out of 8 patents)

7. George A Martin (6 out of 27 patents)

8. Phillip Thomas Hawkins (5 out of 6 patents)

9. Sylvia Braselmann (4 out of 6 patents)

10. Matthew J Hart (4 out of 4 patents)

11. Leisa Johnson (4 out of 4 patents)

12. Julie Nye (4 out of 4 patents)

13. James R Bischoff (4 out of 4 patents)

14. Francis McCormick (4 out of 5 patents)

15. Amy M Delaney (3 out of 3 patents)

Core Competencies:

Peptide Epoxyketone Inhibitors

PIM Kinase Inhibitors

Oncolytic Adenovirus

RAF-MEK-ERK Pathway Inhibitors

Phosphoinositide 3-Kinases

Guanine Exchange Factors

Cytopathic Viruses

Cell Signaling Pathways

Baculovirus Expression System

Nucleotide Sequences

BRCA1 Activity Modulators

Hyperproliferative Cell Growth

58 patents: Sort by Forward Citations

1. 12076363 - Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers (2024-09-03),

2. 8809526 - Synthesis of cyclopentaquinazolines (2014-08-19),

3. 7994294 - Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase (2011-08-09),

4. 7829329 - Adenoviral vectors for treating disease (2010-11-09),

5. 7785887 - Adenovirus E1B-55K single amino acid mutants and methods of use (2010-08-31),

6. 7556955 - [object Object] (2009-07-07),

7. 7442534 - Nucleic acids and polypeptides which resemble Rho and which interact with cell signalling pathways and proteins (2008-10-28),

8. 7414113 - [object Object] (2008-08-19),

9. 7396679 - Oncolytic adenovirus (2008-07-08),

10. 7307071 - RAF-MEK-ERK pathway inhibitors to treat cancer (2007-12-11),

11. 7148002 - Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase (2006-12-12),

12. 7141404 - [object Object] (2006-11-28),

13. 7078030 - Oncolytic adenovirus (2006-07-18),

14. 7001596 - Oncolytic adenovirus (2006-02-21),

15. 6890747 - Phosphoinositide 3-kinases (2005-05-10),

ONYX Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for improving the lives of patients with cancer. With a focus on targeted therapies, ONYX aims to provide groundbreaking treatments that address unmet medical needs. Through collaborations and research, the company strives to advance the field of oncology and transform the way cancer is treated. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

58 Patents

#87 in San Francisco, CA

#1,407 in California

#5,957 in US

#12,003 in the World

San Francisco, CA, United States of America

Onyx Pharmaceuticals, Inc.

Forward Citations = 850

68 inventors:

Terry Hermiston (9 out of 30 patents)

Arie Abo (8 out of 13 patents)

Len Stephens (8 out of 8 patents)

4. Sylvie Laquerre (7 out of 10 patents)

5. Yuqiao Shen (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…